Elicio Therapeutics, Inc. (ELTX) Stock Score, Valuation & Financial Research

Elicio Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ELTX

Elicio Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.82. These figures are a research snapshot, not a buy or sell recommendation.

What Elicio Therapeutics, Inc. does

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Elicio Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future collaborations to fund the research and development of its proprietary lymph node-targeted immunotherapy platform.

Products and services

  • The company is developing a pipeline of novel immunotherapies, including its lead candidate ELI-002, which is designed to target mKRAS-driven cancers such as pancreatic and colorectal cancer.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company competes with various entities developing cancer immunotherapies and vaccines, including those targeting KRAS mutations. Source

Business strengths to evaluate

  • Proprietary lymph node-targeted immunotherapy platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on clinical trial success and regulatory approval Source
  • Need for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ELTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.82
Market capitalization:
34.7M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -37.84M
Free cash flow:
USD -36.97M
Cash:
USD 23.48M
Total debt:
USD 14.15M
EPS:
USD -2.13

What stands out

  • Free cash flow is USD -36.97M, negative for the stored period.
  • The balance sheet shows USD 23.48M of cash versus USD 14.15M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 9.33M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ELTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ELTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ELTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ELTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ELTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ELTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.